Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A phase II dual-cohort trial of conventional-dose versus short-course induction radiotherapy with adebelimumab and chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
ChiCTR2600131718Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Sep 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Pathological complete response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
adebrelimabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600131718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131718.